Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats. // Neuroscience Research. – URL: https://www.sciencedirect.com/science/article/pii/S0168010226001227?dgcid=rss_sd_all
Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats. Neuroscience Research. https://www.sciencedirect.com/science/article/pii/S0168010226001227?dgcid=rss_sd_all
“Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats.” Neuroscience Research.
@article{article9776,
title = {Centrally administered SGLT2 inhibitor improves gut barrier function through the brain orexin, AMPK, dopamine D2 signaling and the vagal pathway in rats},
journal = {Neuroscience Research},
url = {https://www.sciencedirect.com/science/article/pii/S0168010226001227?dgcid=rss_sd_all}
}